Jupiter Neurosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JUNS research report →
Companywww.jupiterorphan.com
Jupiter Neurosciences, Inc. , a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I.
- CEO
- Christer Rosen
- IPO
- 2022
- Employees
- 4
- HQ
- Jupiter, FL, US
Price Chart
Valuation
- Market Cap
- $7.44M
- P/E
- -0.79
- P/S
- 183.88
- P/B
- -2.60
- EV/EBITDA
- -1.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.22%
- Op Margin
- -23075.85%
- Net Margin
- -22690.83%
- ROE
- 1140.91%
- ROIC
- -455.42%
Growth & Income
- Revenue
- $21.80K · 0.00%
- Net Income
- $-8,644,897 · -254.35%
- EPS
- $-0.25 · -194.81%
- Op Income
- $-8,908,721
- FCF YoY
- -38.42%
Performance & Tape
- 52W High
- $3.33
- 52W Low
- $0.17
- 50D MA
- $0.38
- 200D MA
- $0.96
- Beta
- 2.14
- Avg Volume
- 123.07K
Get TickerSpark's AI analysis on JUNS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 2, 25 | Elmasri Saleem | other | 102,128 |
| Jun 2, 25 | Elmasri Saleem | other | 66,293 |
| Jul 2, 25 | Silva Alison D. | other | 255,320 |
| Jul 1, 25 | Silva Alison D. | buy | 250 |
| Jul 1, 25 | Silva Alison D. | buy | 250 |
| Jul 1, 25 | Silva Alison D. | buy | 250 |
| Jul 1, 25 | ROSEN CHRISTER | buy | 3,100 |
| Jul 1, 25 | ROSEN CHRISTER | buy | 500 |
| Jun 30, 25 | Silva Alison D. | buy | 100 |
| Jun 30, 25 | Silva Alison D. | buy | 250 |
Our JUNS Coverage
We haven't published any research on JUNS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate JUNS Report →